Cargando…
γδ T cells in immunotherapies for B-cell malignancies
Despite the advancements in therapy for B cell malignancies and the increase in long–term survival of patients, almost half of them lead to relapse. Combinations of chemotherapy and monoclonal antibodies such as anti-CD20 leads to mixed outcomes. Recent developments in immune cell-based therapies ar...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325712/ https://www.ncbi.nlm.nih.gov/pubmed/37426670 http://dx.doi.org/10.3389/fimmu.2023.1200003 |
_version_ | 1785069279495847936 |
---|---|
author | Rimailho, Léa Faria, Carla Domagala, Marcin Laurent, Camille Bezombes, Christine Poupot, Mary |
author_facet | Rimailho, Léa Faria, Carla Domagala, Marcin Laurent, Camille Bezombes, Christine Poupot, Mary |
author_sort | Rimailho, Léa |
collection | PubMed |
description | Despite the advancements in therapy for B cell malignancies and the increase in long–term survival of patients, almost half of them lead to relapse. Combinations of chemotherapy and monoclonal antibodies such as anti-CD20 leads to mixed outcomes. Recent developments in immune cell-based therapies are showing many encouraging results. γδ T cells, with their potential of functional plasticity and their anti-tumoral properties, emerged as good candidates for cancer immunotherapies. The representation and the diversity of γδ T cells in tissues and in the blood, in physiological conditions or in B-cell malignancies such as B cell lymphoma, chronic lymphoblastic leukemia or multiple myeloma, provides the possibility to manipulate them with immunotherapeutic approaches for these patients. In this review, we summarized several strategies based on the activation and tumor-targeting of γδ T cells, optimization of expansion protocols, and development of gene-modified γδ T cells, using combinations of antibodies and therapeutic drugs and adoptive cell therapy with autologous or allogenic γδ T cells following potential genetic modifications. |
format | Online Article Text |
id | pubmed-10325712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103257122023-07-07 γδ T cells in immunotherapies for B-cell malignancies Rimailho, Léa Faria, Carla Domagala, Marcin Laurent, Camille Bezombes, Christine Poupot, Mary Front Immunol Immunology Despite the advancements in therapy for B cell malignancies and the increase in long–term survival of patients, almost half of them lead to relapse. Combinations of chemotherapy and monoclonal antibodies such as anti-CD20 leads to mixed outcomes. Recent developments in immune cell-based therapies are showing many encouraging results. γδ T cells, with their potential of functional plasticity and their anti-tumoral properties, emerged as good candidates for cancer immunotherapies. The representation and the diversity of γδ T cells in tissues and in the blood, in physiological conditions or in B-cell malignancies such as B cell lymphoma, chronic lymphoblastic leukemia or multiple myeloma, provides the possibility to manipulate them with immunotherapeutic approaches for these patients. In this review, we summarized several strategies based on the activation and tumor-targeting of γδ T cells, optimization of expansion protocols, and development of gene-modified γδ T cells, using combinations of antibodies and therapeutic drugs and adoptive cell therapy with autologous or allogenic γδ T cells following potential genetic modifications. Frontiers Media S.A. 2023-06-22 /pmc/articles/PMC10325712/ /pubmed/37426670 http://dx.doi.org/10.3389/fimmu.2023.1200003 Text en Copyright © 2023 Rimailho, Faria, Domagala, Laurent, Bezombes and Poupot https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Rimailho, Léa Faria, Carla Domagala, Marcin Laurent, Camille Bezombes, Christine Poupot, Mary γδ T cells in immunotherapies for B-cell malignancies |
title | γδ T cells in immunotherapies for B-cell malignancies |
title_full | γδ T cells in immunotherapies for B-cell malignancies |
title_fullStr | γδ T cells in immunotherapies for B-cell malignancies |
title_full_unstemmed | γδ T cells in immunotherapies for B-cell malignancies |
title_short | γδ T cells in immunotherapies for B-cell malignancies |
title_sort | γδ t cells in immunotherapies for b-cell malignancies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325712/ https://www.ncbi.nlm.nih.gov/pubmed/37426670 http://dx.doi.org/10.3389/fimmu.2023.1200003 |
work_keys_str_mv | AT rimailholea gdtcellsinimmunotherapiesforbcellmalignancies AT fariacarla gdtcellsinimmunotherapiesforbcellmalignancies AT domagalamarcin gdtcellsinimmunotherapiesforbcellmalignancies AT laurentcamille gdtcellsinimmunotherapiesforbcellmalignancies AT bezombeschristine gdtcellsinimmunotherapiesforbcellmalignancies AT poupotmary gdtcellsinimmunotherapiesforbcellmalignancies |